Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 4/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | ATM | Q13315 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4528036 | 0.90 | SMN1; SMN2 (0.64) | NPC1SMN1; SMN2RAB9ANUDT1MAPT | |
| SCHEMBL4535234 | 0.88 | CYP1A2 (0.57) | NPC1SMN1; SMN2RAB9ANUDT1MAPT | |
| SCHEMBL7895245 | 0.87 | NUDT1 (0.69) | NPC1SMN1; SMN2RAB9ANUDT1MAPT | |
| SCHEMBL4177914 | 0.83 | SMN1; SMN2 (0.63) | NPC1SMN1; SMN2RAB9ANUDT1MAPT | |
| SCHEMBL9638455 | 0.81 | NUDT1 (0.63) | NPC1SMN1; SMN2RAB9ANUDT1MAPT | |
| SCHEMBL17623918 | 0.81 | MAPT (0.67) | NPC1SMN1; SMN2RAB9ANUDT1MAPT | |
| SCHEMBL11972460 | 0.81 | F10 (0.58) | NPC1SMN1; SMN2RAB9AMAPTMEN1 | |
| SCHEMBL7363505 | 0.79 | SMN1; SMN2 (0.62) | NPC1SMN1; SMN2RAB9ANUDT1MAPT | |
| SCHEMBL23010902 | 0.79 | MAPT (0.63) | NPC1SMN1; SMN2RAB9ANUDT1MAPT | |
| SCHEMBL16441869 | 0.79 | MEN1 (0.75) | NPC1SMN1; SMN2RAB9ANUDT1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090018150-A1 | 5-Ht2b Receptor Antagonists | ASTERAND UK LIMITED (GB) | 2009-01-15 | — | — | US | disclosed |
| US-20090018150-A1 | 5-Ht2b Receptor Antagonists | ASTERAND UK LIMITED (GB) | 2009-01-15 | — | — | US | disclosed |
| US-20090018150-A1 | 5-Ht2b Receptor Antagonists | ASTERAND UK LIMITED (GB) | 2009-01-15 | — | — | US | disclosed |
| US-20060116368-A1 | 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | US | disclosed |
| WO-2006058338-A2 | 4 - PIPERIDINECARBOXAMIDE DERIVATIVES AS MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018150-A1 | 5-Ht2b Receptor Antagonists | HTR2B, HTR1B, HTR3B | NPC1 2993/4885SMN1; SMN2 2157/4885RAB9A 1024/4885 |
| US-20060116368-A1 | 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor | VDAC1, TRPV1, HVCN1 | NPC1 523/4885SMN1; SMN2 4223/4885RAB9A 3793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.